Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPR | P35270 | 13/20 | 0.41 |
| ▸ | NAMPT | P43490 | 2/20 | 0.38 |
| ▸ | VNN1 | O95497 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2706719 | 0.83 | CYP2D6 (0.39) | SPRCYP2D6KCNH2HRH3 | |
| SCHEMBL27872557 | 0.82 | HRH3 (0.47) | SPRNAMPTVNN1CYP2D6KCNH2 | |
| SCHEMBL2825842 | 0.80 | SPR (0.39) | SPRNAMPTVNN1CYP2D6KCNH2 | |
| SCHEMBL15808474 | 0.79 | SPR (0.39) | SPRNAMPTVNN1 | |
| SCHEMBL772535 | 0.78 | SPR (0.38) | SPRNAMPTVNN1CYP2D6KCNH2 | |
| SCHEMBL7860329 | 0.78 | EPHX2 (0.46) | SPRNAMPTKDM4E | |
| SCHEMBL18312206 | 0.78 | SPR (0.41) | SPRNAMPTVNN1CYP2D6KCNH2 | |
| SCHEMBL15114446 | 0.78 | RBP4 (0.46) | SPRNAMPTVNN1CYP2D6KCNH2 | |
| SCHEMBL24549699 | 0.78 | ALDH1A1 (0.58) | SPRNAMPT | |
| SCHEMBL28677057 | 0.76 | PKM (0.33) | SPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102532162-B | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMA CO LTD | 2015-05-27 | — | — | CN | disclosed |
| US-8921404-B2 | Azole derivatives in the form of lipase and phospholipase inhibitors | SANOFI (FR) | 2014-12-30 | — | — | US | disclosed |
| US-20140378436-A9 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their use and Manufacture | EXELIXIS, INC. (US) | 2014-12-25 | — | — | US | disclosed |
| EP-1937648-B1 | DIACYL INDAZOL DERIVATIVES AS LIPASE AND PHOSPHOLIPASE INHIBITORS | SANOFI SA (FR) | 2014-11-26 | — | — | EP | disclosed |
| US-20140066431-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | EXELIXIS, INC. (US) | 2014-03-06 | — | — | US | disclosed |
| US-8637499-B2 | Benzoxazepines as inhibitors of PI3K/mTOR and methods of their use and manufacture | EXELIXIS, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-20140024637-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their use and Manufacture | EXELIXIS, INC. (US) | 2014-01-23 | — | — | US | disclosed |
| EP-2643316-A2 | BENZOXAZEPINES AS INHIBITORS OF P13K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE | Exelixis, Inc. (US) | 2013-10-02 | — | — | EP | disclosed |
| EP-2640367-A2 | BENZOXAZEPINES AS INHIBITORS OF PI3K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE | Exelixis, Inc. (US) | 2013-09-25 | — | — | EP | disclosed |
| EP-2435426-B1 | BENZOXAZEPINES AS INHIBITORS OF PI3K/m TOR AND METHODS OF THEIR USE AND MANUFACTURE | EXELIXIS INC (US) | 2013-05-22 | — | — | EP | disclosed |
| CN-101160293-A | Azole derivatives in the form of lipase and phospholipase inhibitors | SANOFI AVENTIS DEUTSCHLAND (FR) | 2008-04-09 | — | — | CN | disclosed |
| CN-100366624-C | 2, 3-dihydro-6-nitroimidazo [2,1-b ] * azole compounds | OTSUKA PHARMA CO LTD (JP) | 2008-02-06 | — | — | CN | disclosed |
| EP-1874741-A1 | AZOLE DERIVATIVES IN THE FORM OF LIPASE AND PHOSPHOLIPASE INHIBITORS | sanofi-aventis (FR) | 2008-01-09 | — | — | EP | disclosed |
| WO-2007042178-A1 | DIACYL INDAZOL DERIVATIVES AS LIPASE AND PHOSPHOLIPASE INHIBITORS | SANOFI-AVENTIS (DE) | 2007-04-19 | — | — | WO | disclosed |
| CN-1914180-A | Indazole derivatives as hormone sensitive lipase inhibitors | SANOFI AVENTIS DEUTSCHLAND (DE) | 2007-02-14 | — | — | CN | disclosed |
| WO-2006111321-A1 | AZOLE DERIVATIVES IN THE FORM OF LIPASE AND PHOSPHOLIPASE INHIBITORS | SANOFI-AVENTIS (DE) | 2006-10-26 | — | — | WO | disclosed |
| EP-1713779-A1 | INDAZOLE DERIVATIVES AS INHIBITORS OF HORMONE-SENSITIVE LIPASES | Sanofi-Aventis Deutschland GmbH (DE) | 2006-10-25 | — | — | EP | disclosed |
| CN-1705670-A | 2, 3-dihydro-6-nitroimidazo [2, 1-b ] oxazole compounds | OTSUKA PHARMA CO LTD (JP) | 2005-12-07 | — | — | CN | disclosed |
| US-20050197348-A1 | Indazole derivatives as inhibitors of hormone sensitive lipase | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-09-08 | — | — | US | disclosed |
| WO-2005073199-A1 | INDAZOLE DERIVATIVES AS INHIBITORS OF HORMONE-SENSITIVE LIPASES | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2005-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378436-A9 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their use and Manufacture | MTOR, RICTOR, PIK3CA | SPR 3549/4885NAMPT 499/4885VNN1 1852/4885 |
| US-20140024637-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their use and Manufacture | MTOR, RICTOR, PIK3CA | SPR 3549/4885NAMPT 499/4885VNN1 1852/4885 |
| US-20140066431-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | MTOR, RICTOR, PIK3CA | SPR 3501/4885NAMPT 450/4885VNN1 1878/4885 |
| US-20050197348-A1 | Indazole derivatives as inhibitors of hormone sensitive lipase | LIPE, PNLIP, CEL | SPR 2612/4885NAMPT 2011/4885VNN1 2104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.